CLINAM 7/2014 - Conference and Exhibition, Basel, June 22-25, 2014

The European Summit for Clinical Nanomedicine and Targeted Medicine

Paving the Way to Personalized Diagnostics & Personalized Medicine

Call for Papers and Posters

The European Foundation for Clinical Nanomedicine (CLINAM) and the European Technology Platform on Nanomedicine (ETPN) invite you to participate in CLINAM 7/2014, the 7th European Summit for Clinical Nanomedicine and Targeted Medicine, the reference conference in Europe for the field. This indispensable worldwide platform brings together Clinical Nanomedicine and Targeted Medicine in the generic context with Personalized Medicine and the international debate platform on precise, highly effective novel spheres of Medicine. This year’s focus topic is: **Paving the Way to Personalized Diagnostics & Personalized Medicine.**

**Participate Actively in the Debate Conference and Exhibition of CLINAM 7/2014**

- Bridging event between research, translation, and clinical application in Nanomedicine and Targeted Medicine and its consequences for tomorrow’s medicine
- The focus on Personalized Medicine through Diagnostic Nanotechnologies and Targeting Platforms for Imaging and Therapy
- Help to shape the worldwide community of leaders in nanomedicine and targeted delivery, researchers, clinicians, industrial experts, investors, policy makers, regulatory authorities, and all those investing in tomorrow’s diagnostics, therapy and individualization in medicine
- Debate the topics:  • Targeted therapies • Late breaking and ongoing clinical trials, novel materials, technologies and devices • Novel drug delivery and diagnostics for diseases such as cancer, diabetes, infection and inflammation, brain diseases, cardiovascular disease, malaria and more • Translation of novel technologies to market and patient • Regulatory pathways and harmonization of standards • Immunology, toxicology and implications • Financing developments • Nanomedicine market trends • Ethical and societal implications • Results of European Union research projects and national initiatives • Future European and national healthcare policies
- Participate in the panel session on the UN Right to Health
- Profit from the large Exhibition of Innovations, Products and Services related to the fields of the participants

Organizers Office: European Foundation for Clinical Nanomedicine, Alemannengasse 12
CH 4016 Basel, Switzerland Phone +41 61 695 93 95
E-Mail clinam@clinam.org website www.clinam.org
Scientific Committee of the Conference

- Prof. Dr. med. Patrick Hunziker, University Hospital Basel (CH) (Chairman)
- Prof. Dr. Yechezkel Barenholz, Hebrew University, Hadassah Medical School, Jerusalem (IL)
- Beat Löffler, MA, European Foundation for Clinical Nanomedicine (CLINAM), Basel (CH)
- Prof. Dr. Gert Storm, Institute for Pharmaceutical Sciences, Utrecht University, Utrecht (NL)
- Prof. Dr. Marisa Papaluca Amati, European Medicines Agency, London (GB)
- Prof. Dr. med. Janos Szebeni, Bay Zoltan Ltd and Semmelweis/Miskolc Universities, Budapest (HU)
- Prof. Dr. med. Christoph Alexiou, Head and Neck Surgery, University Hospital Erlangen (DE)
- Prof. Dr. Claus-Michael Lehr, Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS), Saarbrucken (DE)
- Patrick Boisseau, CEA-Léti, Chairman of the Board of the ETPN. Grenoble (FR)
- Prof. Dr. Viola Vogel, Laboratory for Biologically Oriented Materials, ETH, Zürich (CH)
- Prof. Dr. Jan Mollenhauer, University of Southern Denmark and NanoCAN, Odense (DK)
- Dr. Yanay Ofran, Systems Biology & Functional Genomics, Bar Ilan University, Ramat Gan (IL)
- Gerd Binnig Founder of Definiens, Nobel Laureate (tbc) (DE)

Joint Collaborators

- European Foundation for Clinical Nanomedicine (CLINAM), Basel (CH)
- European Technology Platform on Nanomedicine (ETPN), Berlin (DE)
- The International Association for Pharmaceutical Technology, Focus Group “Drug Delivery” (APV), Mainz (DE)
- European Society for Nanomedicine (ESNAM), Basel (CH)
- International Society for Nanomedicine (ISNM) Basel (CH)
- European Medicines Agency EMA., London (tbc) (GB)
- Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Saarbrucken (DE)
- BioNanoNet Research Association” (BioNanoNet), Graz (AT)
- EU, Directorate-General for Research & Innovation (RTD), Brussels (BE)
- Eur. Association for Predictive and Preventive and Personalized Medicine (EPMA) Brussels (BE)
- European Platform for Photodynamic Medicine (EPPM), Hull (GB)
- European Materials Research Society (E-MRS), Strasbourg (FR)

Conference Paper and Poster Submissions

Papers must cover original research aimed at future or current applications of nanoscience and targeted medicine including clinical trial designs, reports of ongoing and completed clinical trials, preclinical work, and technology papers with clinical long-term vision. All fields leading to the development of personalized medicine are also issues of interest.

- **Clinical Topics:**
  - Nanomedicine and targeted medicine for cardiovascular disease, rheumatic disease, oncology, gastrointestinal/hepatic disease, bacterial infection, viral infection, parasitic infection, implantology, infection, hematology, neurology, neurosurgery, inflammation, orphan diseases, eye and ear disease, tuberculosis, HIV, tissue repair, orthopedics, etc.

- **Sessions on Technology:**
  - Nano-systems, nano-particles, nano-analytics and diagnostics, toxicology, nano-imaging, targeted drug delivery using nanoparticles, GMP and quality assurance, propositions for solving a medical problem in a novel way by the use of nano-technology, novel concepts and ideas if they can be supported by thorough reasoning and could lead to novel research and solutions, materials for use in nanotechnology and targeted medicine, concepts, diagnosis and therapy in the field of personalized medicine: clinical diagnosis and management on
the individual patient's clinical signs and symptoms, medical and family history, and data from laboratory and imaging evaluation to diagnose and treat illnesses, genetic testing leading to more personalized treatments.

- **Sessions on the Implications:**
  Implications of nanomedicine for society, developing countries, environment, risks and benefits, public health finance, health economics, and other subjects.

- **Sessions on Strategy, Government, Politics**
  Strategy building and policy processes in nanomedicine. Strategic approaches towards establishing a unified funding area for nanotechnologies for medical research. Policy processes to foster leadership in nanomedicine, regulatory authority topics as well as financial and marketing matters. **Industry:** Industry projects and solutions in nanomedicine and targeted medicine, tools related to nanomedicine and targeted medicine.

- **Sessions of the Exhibitors**
  Integrated interventions of exhibitors at CLINAM 7/14 in integrated sessions.

**Submission Format and Procedure**

Send us your paper or poster abstract, a short CV and your portrait photo in gif or jpg to submiss2014@clinam.org, naming your file as follows: Last name.First name_Submission14(xx ). The submission must be written in Microsoft Word, RTF, or Open document file format, using Times New Roman, font size 12, with single spacing and must not be longer than three pages, including metadata and figures (one figure is obligatory). All illustrations, figures, and tables are placed within the text at the appropriate points. In addition you are asked to enclose your short CV (max. 1 page), a portrait photo in high resolution (jpg or gif and not Word copy paste!)- Here, too, please make sure you name your files as follows: LastName.Firstname.CV.xx and LastName.Firstname_Picture.xx . The decision to acceptance or reject your submitted work will be taken by April 5, 2014. You will receive a Decision Form, which – in the case of acceptance - has to be returned within 3 days of receipt. After this you have to register according to your category.

**Registration Fees for the Conference including the Exhibition**

<table>
<thead>
<tr>
<th>Category</th>
<th>Currency is Euro</th>
<th>Early until 15.1.14</th>
<th>Regular until 23.5.14</th>
<th>Fellowships until 22.6.14</th>
<th>1 Day Early until 15.1.14</th>
<th>1 Day Regular until 22.6.14</th>
</tr>
</thead>
<tbody>
<tr>
<td>Academy</td>
<td></td>
<td>475.--</td>
<td>650.--</td>
<td>400.--</td>
<td>180.--</td>
<td>220.--</td>
</tr>
<tr>
<td>Government</td>
<td></td>
<td>825.--</td>
<td>875.--</td>
<td>650.--</td>
<td>280.--</td>
<td>300.--</td>
</tr>
<tr>
<td>Industry</td>
<td></td>
<td>1100.--</td>
<td>1250.--</td>
<td>900.--</td>
<td>380.--</td>
<td>450.--</td>
</tr>
<tr>
<td>Exhibitors</td>
<td></td>
<td>700.--</td>
<td>800.--</td>
<td>550.--</td>
<td>350.--</td>
<td>400.--</td>
</tr>
<tr>
<td>Students</td>
<td></td>
<td>385.--</td>
<td>480.--</td>
<td>295.--</td>
<td>190.--</td>
<td>170.--</td>
</tr>
<tr>
<td>Subm. Speakers</td>
<td></td>
<td>550.--</td>
<td>600.--</td>
<td>380.--</td>
<td>230.--</td>
<td>310.--</td>
</tr>
</tbody>
</table>

Your contribution to the Brokerage Dinner on Monday, June 23, 2014, 8.15 pm is € 60 and is extra.

Members of the European Society for Nanomedicine benefit from a 10% reduction (registration under esnam.org)

Late registration after May 23, 2914 entails a 20% surcharge on regular fees to be paid at the registration desk

**Target Audience**

The faculty includes the pioneers and opinion leaders in the fields of medicine, nanoscience and targeted medicine, who share their experience in an interdisciplinary and interactive manner that widens mutual understanding for both sides.

The conference and the exhibition are aimed at physicians, as well as nanoscientists with a background in pharmacology, biology, physics, chemistry, biophysics, medicine materials science and engineering. The meeting is a particularly useful source of knowledge for the targeted medicine and delivery community. The Conference is also of interest for policymakers, experts from industry in the field of life sciences, developers of new tools and materials for
nanomedicine, and all those investigating the future potential of emerging technologies. Experts from venture companies can acquire knowledge on existing and upcoming developments and novel products in the emerging field of nanomedicine. Government authorities can profit from the regulator’s sessions.

Some Speakers at the 2014 Summit

- Prof. Dr. med. Aaron Ciechanover, Nobel laureate, Tumor and Vascular Biology Research Center The Rappaport Faculty of Medicine and Research Institute Technion - Israel Institute of Technology, Haifa (IL)
- Prof. Dr. med. Omid Farokhzad, Director, Lab of Nanomedicine and Biomaterials, Associate Professor, Harvard Medical School Brigham and Women's Hospital Boston, (US)
- Prof. Dr. med. Christoph Alexiou, Head and Neck Surgery, University Hospital Erlangen (DE)
- Prof. Dr. Yechezkel Barenholz, Hebrew University, Hadassah Medical School, Jerusalem (IL)
- Patrick Boisseau, CEA-LétI, Head of Business Development Nanomedicine and Chairman of the European Technology Platform on Nanomedicine, Grenoble (FR)
- Prof. Dr. Lajos P. Balogh, Editor-in-Chief, Nanomedicine: Nanotechnology, Biology and Medicine (Elsevier), Boston (US)
- Prof. Dr. med. Vincenzo Costigliola, President of the European Medical Association (EMA), President of the European Association for Predictive and Preventive & Personalized Medicine (EPMA), Brussels (BE)
- Prof. Dr. Rutledge Ellis-Behnke, Director of the Nanomedicine Translational Think Tank, Department of Ophthalmology, Medical Faculty Mannheim, University of Heidelberg (DE)
- Prof. Dr. M. Foldvari, DPharmSci, Canada Research Chair in Bionanotechnology and Nanomedicine, School of Pharmacy, University of Waterloo (CA)
- Prof. Dr. med. Patrick Hunziker, President of the European Society for Nanomedicine, Basel, (CH)
- Dr. Peter van Hoogeveest, Head Scientific Department, Lipoid GmbH, Heidelberg(DE)
- Dr. Julianna Lisziewicz, CEO, Genetic Immunity, Budapest (HU)
- Beat Löffler MA, CEO of the European Foundation for Nanomedicine, Basel (CH)
- Prof. Dr. Witold Łojkowski, Head of the Instytut Wysokich Ciśnień PAN, Institute of High Pressure Physics, Polish Academy of Sciences, Warsaw (PL)
- Prof. Dr. Jan Mollenhauer, University of Southern Denmark Head Molecular Oncology Director of Lundbeckfonden Center of Excellence in Nanomedicine NanoCAN, Odense (DK)
- Prof. Dr. Marisa Papaluca Amati, Head of Scientific Support and Projects, European Medicines Agency, London (GB) (tbc)
- Dr. Bernd Riebesehl, Principal Fellow, Novartis Pharma, Basel (CH)
- Prof. Dr. Eder Lilia Romero Programa de Nanomedicas, Universidad Nacional de Quilmes, Buenos Aires (AR)
- Dr. Ruth Schmid, Chief Business Developer SINTEF Materials and Chemistry Synthesis and Properties Polymer Particles and Surface Chemistry, Trondheim (NO)
- Prof. Dr. G. Scoles, University Hospital, University of Udine, Udine (IT) and Biology Department, Temple University, Philadelphia, PA (US)
- Prof. Dr. Gert Storm, Institute for Pharmaceutical Sciences, Utrecht University, Utrecht (NL)
- Dr. Rudolf Strohmeier, Deputy Director General of the DG for Research, Brussels (BE)
- Prof. Dr. med. Simo Schwartz, Jr., PhD, Research Center for Nanomedicine (CIBBIM-Nanomedicine) Vall d’Hebron Univ. Hospital Research Institute, Barcelona (ES)
- Prof. Dr. med. Janos Szebeni, Director, Nanomedicine Research and Education Center, Bay Zoltan Ltd/Semmelweis / Miskolc Universities, Budapest (HU)
- Prof. Dr. Donald Tomalia, Columbia University, NY, NY, Affiliate Professor Virginia Common-wealth University, Richmond, VA, CEO/Founder NanoSynthons LLC National Dendrimer & Nanotechnology Center, Mt. Pleasant MI, External Faculty (School of Pharmacy), University of Wisconsin, Madison, WI (US)
- Prof. Dr. Viola Vogel, Department of Materials Laboratory for Biologically Oriented Materials, ETH Zürich, Zürich (CH)

“Small Speech” Sessions

Poster presenters and University Village members are eligible for presentations in a special session of Small Speeches, 3 minutes in length and serving to highlight the research activities in Nanotechnology and Targeted Medicine. They must comprise three slides, Slide 1: general introduction to the topic • Slide 2: some of the highlights of submitters’ work and institutions’ work • Slide 3: the proof as to how the work fits into the area of nanomedicine including a glimpse into the future. Application for Small Talk Sessions is possible any time after acceptance of your poster in writing.